Dopamine News and Research

Latest Dopamine News and Research

IUPUI develops mathematical model of brain's neural circuitry

Researchers from the School of Science at Indiana University-Purdue University Indianapolis have developed a mathematical model of the brain's neural circuitry that may provide a better understanding of how and why information is not transmitted correctly in the brains of Parkinson's disease patients. This knowledge may eventually help scientists and clinicians correct these misfires.

28 Sep 2011

BioLineRx's BL-1020 Phase IIb EAGLE trial data on schizophrenia to be presented at ECSR

BioLineRx, a biopharmaceutical development company, today announced that data from the successfully completed Phase IIb EAGLE study of BL-1020, a first in class GABA-enhanced antipsychotic for the treatment of schizophrenia, will be presented at the 3rd European Conference on Schizophrenia Research (ECSR) held in Berlin, Germany.

28 Sep 2011

Anti-obesity drug Contrave may get another chance to prove itself

With rise obesity around the world there should have been a number of drugs to combat it. The reality is different. There are no safe and effective drugs in the market at present.

22 Sep 2011

Jefferson experts review most commonly used CAM practices for mood disorders

Mood disorders are among the most prevalent mental health issues today. While medication is available, more and more people are turning to complementary and alternative medicine (CAM), including herbal remedies, acupuncture, and meditation to help manage their mood disorders.

22 Sep 2011

Methylphenidate drug may induce arousal from general anesthesia

Administration of the commonly used stimulant drug methylphenidate (Ritalin) was able to speed recovery from general anesthesia in an animal study conducted at Massachusetts General Hospital.

22 Sep 2011

Lund University professor receives Fernström Foundation Nordic Prize for brain cell transplants

This year's Fernström Foundation Nordic Prize, with prize money of SEK 1 million, goes to Professor Anders Björklund from Lund University, Sweden. He is a neurology researcher focusing on neurodegenerative diseases, diseases in which the nerve cells die. Professor Björklund's research group is trying to develop customised stem cells to treat Parkinson's disease.

12 Sep 2011

PKC epsilon enzyme might be target for treatment of nicotine addiction, alcohol abuse

An enzyme that appears to play a role in controlling the brain's response to nicotine and alcohol in mice might be a promising target for a drug that simultaneously would treat nicotine addiction and alcohol abuse in people, according to a study by researchers at the Ernest Gallo Clinic and Research Center, affiliated with the University of California, San Francisco.

9 Sep 2011

Sagene completes SPI-1972 pre-IND meeting with FDA for erectile dysfunction

Sagene Pharmaceuticals, Inc., a biopharmaceutical company focused on developing combinations of FDA-approved drugs to treat diseases associated with aging, has completed a pre-IND meeting with the Division of Reproductive and Urologic Products of the FDA to discuss the development plan for SPI-1972, a dual-action combination treatment for erectile dysfunction.

9 Sep 2011

Scientist identifies how lack of dopamine leads to symptoms of Parkinson's

A scientist at the Gladstone Institutes has identified how the lack of a brain chemical known as dopamine can rewire the interaction between two groups of brain cells and lead to symptoms of Parkinson's disease.

8 Sep 2011

Scientists discover two opposing neuronal regulatory circuits for generation, elimination of fear

Emotional balance is regulated by molecular factors behind stress response. When healthy people are faced with threatening situations, they react with a suitable behavioural response and do not descend into a state of either panic or indifference, as is the case, for example, with patients who suffer from anxiety.

7 Sep 2011

UTHealth to study BMS-820836 in Phase II trial for major depressive disorder

A new medication to treat major depressive disorder in patients who have not responded to other antidepressants is being studied in a Phase II clinical trial by researchers at The University of Texas Health Science Center at Houston.

2 Sep 2011

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

It’s said a lot can happen in seven days. In seven years, a lot has happened in the understanding of acromegaly, a debilitating condition that causes a patient to have too much growth hormone. It’s seven years since the American Association of Clinical Endocrinologists last produced guidelines for the diagnosis and treatment of acromegaly. Their 2004 guidelines were just 13 pages long. Their latest, the 2011 guidelines, have grown – to 44 pages.

31 Aug 2011

DaTscan allows doctors to differentiate Parkinson's from other movement disorders

Thanks to a new diagnostic imaging technique, physicians now have an objective test to evaluate patients for parkinsonian syndromes, such as Parkinson's disease. Northwestern Memorial Hospital is among the first institutions in the country to offer DaTscan-, the only FDA-approved imaging agent for assessment of movement disorders.

26 Aug 2011

Researchers discover how antipsychotic drugs manage symptoms of schizophrenia

The classic symptoms of schizophrenia - paranoia, hallucinations, the inability to function socially-can be managed with antipsychotic drugs. But exactly how these drugs work has long been a mystery.

25 Aug 2011

Parkinson’s disease breakthrough with stem cell research

A new stem cell study has raised hopes for therapy in Parkinson's disease. Researchers said they have, for the first time, generated stem cells from one of the most rapidly-progressing forms of the disease. They said the development will boost research into the condition because it will allow scientists to model the disease in laboratories and help them shed light on why certain nerve cells die. The research was led by the University of Edinburgh in collaboration with University College London (UCL).

24 Aug 2011

Health Canada accepts Sunovion Pharmaceuticals Canada's lurasidone NDS for review

Sunovion Pharmaceuticals Canada Inc., formerly Sepracor Pharmaceuticals, Inc., today announced that the New Drug Submission (NDS) for Lurasidone HCl, for the treatment of adult patients with schizophrenia has been accepted for review by Health Canada. The NDS was submitted to Health Canada in June 2011 and will receive a standard review.

24 Aug 2011

Scientists identify molecular pathway that plays a key role in stress-related DNA damage

Working closely with a team of researchers from Duke University, scientists from the Florida campus of The Scripps Research Institute have helped identify a molecular pathway that plays a key role in stress-related damage to the genome, the entirety of an organism's hereditary information.

23 Aug 2011

Risk of Parkinson's disease increases with traumatic brain injury and exposure to pesticide paraquat

Traumatic brain injury has entered the public's consciousness as the silent, signature wound brought back by many of our military warriors from Iraq and Afghanistan. But such injuries don't only happen in warfare, they happen to civilians too. Think car crashes, a slip and fall, two football players colliding helmet to helmet.

22 Aug 2011

More kids being diagnosed with ADHD

A new study revealed that number of children diagnosed with Attention Deficit Hyperactivity disorder or ADHD has risen sharply over the last decade.

18 Aug 2011

Scientists artificially grow brain cells from Parkinson's patients to find treatment

The UK's population is ageing and with it comes an increased risk of developing age-related diseases such as Parkinson's. About 70% of dopamine producing brain cells will have been lost by the time a sufferer visits the doctor, with symptoms that include difficulties with movement and a resting tremor. A progressive neurodegenerative disease, Parkinson's affects about 120,000 people in the UK.

18 Aug 2011

Dopamine News and Research

Latest Dopamine News and Research

IUPUI develops mathematical model of brain's neural circuitry

BioLineRx's BL-1020 Phase IIb EAGLE trial data on schizophrenia to be presented at ECSR

Anti-obesity drug Contrave may get another chance to prove itself

Jefferson experts review most commonly used CAM practices for mood disorders

Methylphenidate drug may induce arousal from general anesthesia

Lund University professor receives Fernström Foundation Nordic Prize for brain cell transplants

PKC epsilon enzyme might be target for treatment of nicotine addiction, alcohol abuse

Sagene completes SPI-1972 pre-IND meeting with FDA for erectile dysfunction

Scientist identifies how lack of dopamine leads to symptoms of Parkinson's

Scientists discover two opposing neuronal regulatory circuits for generation, elimination of fear

UTHealth to study BMS-820836 in Phase II trial for major depressive disorder

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

DaTscan allows doctors to differentiate Parkinson's from other movement disorders

Researchers discover how antipsychotic drugs manage symptoms of schizophrenia

Parkinson’s disease breakthrough with stem cell research

Health Canada accepts Sunovion Pharmaceuticals Canada's lurasidone NDS for review

Scientists identify molecular pathway that plays a key role in stress-related DNA damage

Risk of Parkinson's disease increases with traumatic brain injury and exposure to pesticide paraquat

More kids being diagnosed with ADHD

Scientists artificially grow brain cells from Parkinson's patients to find treatment

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Dopamine News and Research

Latest Dopamine News and Research

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Newsletters you may be interested in